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A 75-year-old woman came to the hospital with malaise, mental
obtundation and inflammatory lesions in the left elbow (Figures
1 and 2). She was rushed to hospital 3 h after arriving for
vacation in Madrid from Nicaragua.
She had been suffering from type II diabetes mellitus for 15
years.
On admission, the patient was febrile (38.5 "C), tachycardic,
tachypneic and hypotensive (blood pressure 90/60 mmHg).
Blood cultures were drawn. Thoracic and left elbow radio-
graphs were taken without significant findings. An arthrocent-
esis from the elbow drained 20 mL of synovial fluid. A lumbar
puncture was performed. Analytic data were immediately
collected (Table 1).
Three hours later, several skin lesions appeared over the
patient's right foot, in the 2nd and 3rd toes, the dorsum and
the heeL The evolution of these lesions after 48 h is shown in
Figures 3-5.
Figure 1
nUESTlONS
Discuss the case, considering the following points:
1. What is the etiology of this entity?
2. What are its mechanisms of pathogenicity and the viru-
lence factors associated with the mlcroorgamsms
involved?
3. Is there any method for rapid and specific diagnosis of this
infection?
4. Comment on what is the elective and adjuvant treatment
of this disease.
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Figure 5
Figure 3
Figure 6
Table 1 Analytic data on admission
Blood
ESR117 mrn/t" hour
Hemoglobin 8.8 g/dl
Hematocrit 26.1 %
leukocytes 14 600/III
Count 88% neutrophils
Glucose 190 mg/d l
Figure 4
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Synovial fluid
Yellowish color
low viscosity
Cells: 57 OOO/ill
> 80% neutrophils
Glucose 403 mg/dl
Cerebrospinal fluid
Transparent
Pressure79 rnml-l-O
Proteins 30 mg/d l
Cells:1-2/lll
Monocytes
Glucose 101mg/d l
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CLINICAL OUTCOME
The Gram stain from the synovial fluid showed the presence of
Gram-positive cocci arranged in chains. Rapid antigen detec-
tion for Streptococcus pyogenes (group A streptococci (GAS))
polysaccharide (PSC) in synovial fluid was also positive. Blood
cultures and cultures from synovial fluid and skin biopsies grew
GAS (Figure 6).
The patient was treated initially with intravenous penicillin
(2 million IU every 4 h) but skin surgical debridement of
the lesions was also necessary. Seven days later, intravenous
clindamycin was added (600 mg every 6 h) to the treatment
but the extension of the right foot lesions made amputation
mandatory.
No other septic foci were detected and the patient was
uneventfully discharged 20 days after admission.
DIAGNOSIS
Group A streptococcal gangrene.
DISCUSSION
1. The diagnosis of the skin and soft tissue infections is very
broad. Skin, fascia and muscles are involved, and this also
produces septic arthritis, bacteremia and sepsis [1-4]. Among
the microorganisms able to produce such infections, we must
include Staphylococcus, Streptococcus and Gram-positive anaerobic
bacilli like Clostridium spp., although the Enterobacteriaceae,
other anaerobic bacteria, Pseudomonas and some fungi can
severely affect soft tissues, with systemic impairment [4,5]. In
this case, the microbiological data confirm the diagnosis of
Streptococcus pyogenes gangrene [6-10].
{3-Hemolytic Streptococcus from group A ofLancefield (GAS),
or Streptococcus pyogenes, is a Gram-positive bacterium that is
arranged in chains and grows on blood agar cultures. It is
catalase negative, susceptible to bacitracin and able to hydrolyze
pirrolydonil betanaphthylamide (PYR). In blood agar cultures,
the colonies produce an area of complete hemolysis (f3) caused
by the production of two hemolysins (streptolysins S and 0)
[11]. Their wall is formed by a PSC characteristic of group A
and some structural proteins (proteins M, Tand R). On the basis
of typing M protein, GAS can be differentiated into more than
70 different serotypes. This protein induces antibodies which
react with the cardiac tissue and are responsible for the patho-
genesis of rheumatic fever [12]. Most of the strains of GAS
responsible for invasive diseases are ofthe serotypes Ml and M3,
although clusters of serious infections (shock, multiple organ
failure) with other serotypes, MI0, M12, M28 and M38, have
been reported [13-15].
2. GAS frequendy colonizes the human mucous mem-
branes, particularly those of the upper respiratory tract (tonsils,
pharynx), the gastrointestinal tract, the vagina and wet and
warm skin folds [13,16,17].
The main virulence factors in this microorganism are: pep-
tidoglycan and lipoteicoic acid, M protein, hemolysins (S and 0
streptolysins), enzymes (hyaluronidase, adenase and streptoqui-
nase) and toxins [14,15,18-23].
3. Microbiological diagnosis [1,3,13]. The elements of an
early diagnosis for such infections are: (a) direct sampling
staining (skin biopsies, tissues, fascia, muscle, purulent exudate
or arthrocentesis fluid) with traditional methods-Gram, acri-
dine orange-and special histopathologic stains, such as
Brown-Hopps Gram, Brown-Brenn Gram, Giemsa, Gomori;
(b) rapid detection ofcapsular and protein antigens in skin and/
or tissues-commercial kits for specific antigen are already
available, with sensitivity between 60% and 91% and specificity
between 85% and 98% [24]; (c) culture-in 18 h, we can
observe the growth of typical {3-hemolytic colonies in cultures
on blood agar; (d) molecular techniques for bacterial detection
of genome-these are not available in most laboratories.
4. For the treatment of non-severe infections, intravenous
penicillin G 1-2 million U every 4 h is an adequate option
[25,26]. In severe and invasive infections, although susceptible
in vitro, the in vivo susceptibility of GAS is diminished. This
type of 'resistance' may be caused by several factors, including
the so-called 'Eagle' effect [27], limited postantibiotic effect,
short duration of action of penicillin, in situ production of {3-
lactamases by other microorganisms (saprophytes) and the
phenomenon of tolerance [28-30].
At the present time, combined treatment with clindamycin is
preferred [28]. Its effectiveness is based on the following: (a) it is
not affected by the size of the inoculum or the state ofbacterial
growth; (b) it is a powerful inhibitor ofbacterial toxin synthesis;
(c) it facilitates phagocytosis when inhibiting the synthesis ofM
protein; (d) it has a prolonged postantibiotic effect; and (e) it
inhibits the synthesis ofTNF induced by polysaccharide (PSC)
in the monocytes.
The neutralization of circulating toxins by means of hyper-
immune immunoglobulins is desirable, although its use has
achieved clinical success ouly in cases ofGAS invasive infections
[31]. The dose and suitable duration of therapy are still not
standardized. In this case, we used intravenous immunoglobulin
at doses of 150 mg/kg per day for 10 days.
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